| Metric | Value | Detail |
|---|---|---|
| Revenue | $402.1B | +7.8% YoY |
| Net income | $1.8B | 0.4% margin |
| Gross margin | n/a | No gross profit line in the SEC data |
| Operating margin | 1.2% | Operating income / revenue |
| Return on equity | 2% | Net income / equity |
| Return on assets | 1% | Net income / assets |
| Revenue growth (YoY) | +7.8% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +7.6% | Compound annual |
| Diluted EPS | $1.39 | FY2025 |
| Debt-to-equity | 0.80 | Long-term debt / equity |
| Current ratio | 0.84 | Current assets / liabilities |
| Cash & equivalents | $8.7B | Balance sheet |
| Total assets | $253.5B | FY2025 year-end |
| Shareholders’ equity | $75.2B | FY2025 year-end |
| Share price | $85.90 | Delayed · 2026-10-02 |
| Market cap | $109.9B | Price × shares outstanding |
| P/E ratio | 62.1 | Market cap / net income |
| P/S ratio | 0.3 | Market cap / revenue |
| Dividend yield | 3.10% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
CVS HEALTH CORPORATION (CVS) stock fundamentals
CVS HEALTH CORPORATION (CVS) reported $402.1B in revenue and $1.8B in net income in fiscal 2025, a 0.4% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $109.9B at a delayed share price. It scores 25/100 on WealthyBud's Investor Score, ranking #101 of 103 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$402.1B
▲ +7.8% YoY
Net income
$1.8B
0.4% net margin
Market cap
$109.9B
Price $85.90 · delayed
P/E ratio
62.1
Price / earnings
Return on equity
2%
Net income / equity
Investor Score
25/100
#101 of 103 covered
CVS HEALTH CORPORATION fundamentals at a glance
The table summarizes CVS HEALTH CORPORATION's key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is CVS HEALTH CORPORATION?
CVS HEALTH CORPORATION posted a 0.4% net margin in fiscal 2025, turning $402.1B of revenue into $1.8B of net income. Its return on equity was 2% and its return on assets 1%.
Is CVS HEALTH CORPORATION growing?
CVS HEALTH CORPORATION's revenue changed +7.8% in fiscal 2025 and compounded at +7.6% a year over three years, reaching $402.1B. Diluted earnings per share were $1.39 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $292.1B | First year shown |
| 2022 | $322.5B | +10.4% |
| 2023 | $357.8B | +10.9% |
| 2024 | $372.8B | +4.2% |
| 2025 | $402.1B | +7.8% |
How is CVS HEALTH CORPORATION valued?
CVS HEALTH CORPORATION carries a market capitalization of $109.9B at a delayed share price of $85.90. It trades at 62.1 times earnings and 0.3 times sales. Its dividend yield is 3.10%. Its Value subscore is 64/100 across the covered universe.
How financially healthy is CVS HEALTH CORPORATION?
CVS HEALTH CORPORATION ended fiscal 2025 with $8.7B in cash, a debt-to-equity ratio of 0.80 and a current ratio of 0.84. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is CVS HEALTH CORPORATION's Investor Score?
CVS HEALTH CORPORATION scores 25/100 on WealthyBud's Investor Score, #101 of 103 covered companies as of 2026-10-02. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
25/100
#101 of 103 covered companies
Subscores are percentile ranks (0–100) across the 103 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
CVS HEALTH CORPORATION (CVS) stock FAQ
How much revenue does CVS HEALTH CORPORATION make?
CVS HEALTH CORPORATION (CVS) reported $402.1B in revenue in fiscal 2025, +7.8% versus the prior year, according to its SEC 10-K filing. Its revenue compounded at +7.6% a year over three years.
Is CVS HEALTH CORPORATION profitable?
Yes. CVS HEALTH CORPORATION earned $1.8B in net income in fiscal 2025, a 0.4% net margin. Its return on equity was 2% and its return on assets 1%. These figures come from its latest 10-K.
How fast is CVS HEALTH CORPORATION growing?
CVS HEALTH CORPORATION's revenue changed +7.8% year over year in fiscal 2025 and compounded at +7.6% a year over three years. Growth is one of five inputs to its WealthyBud Investor Score, scored 40/100 versus the covered universe.
What is CVS HEALTH CORPORATION's market cap and P/E ratio?
CVS HEALTH CORPORATION has a market capitalization of $109.9B at a delayed share price of $85.90. It trades at 62.1 times earnings and 0.3 times sales. Its dividend yield is 3.10%. Prices are delayed and illustrative.
What is CVS HEALTH CORPORATION's WealthyBud Investor Score?
CVS HEALTH CORPORATION scores 25/100, ranking #101 of 103 covered companies as of 2026-10-02. The score is a percentile blend of growth (40), profitability (2), returns on capital (3), balance-sheet strength (30) and value (64). It is a research opinion, not investment advice.
Where does this CVS HEALTH CORPORATION financial data come from?
Fundamentals come from CVS HEALTH CORPORATION's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from CVS HEALTH CORPORATION’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-10-02. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.
Related
More large-cap stocks
Stocks
Medtronic plc (MDT)
$110.4B market cap · Investor Score 47/100
View StocksStarbucks Corporation (SBUX)
$107.7B market cap · Investor Score 26/100
View StocksAltria Group, Inc. (MO)
$112.2B market cap · Investor Score 53/100
View ResearchU.S. Stock Market Statistics (2026)
Market cap, valuation and concentration data across the U.S. stock market.
View